Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort

被引:1
|
作者
Ruiz-Irastorza, Guillermo [1 ]
Paredes-Ruiz, Diana [2 ]
Herrero-Galvan, Maria [3 ]
Moreno-Torres, Victor [4 ]
Hernandez-Negrin, Halbert [5 ,6 ]
Ruiz-Arruza, Ioana [1 ]
Leonard, Cedric [7 ]
Richez, Christophe [7 ]
Lazaro, Estibaliz [7 ]
机构
[1] Univ Basque Country, UPV EHU, Biobizkaia Hlth Res Inst, Bizkaia, Spain
[2] Biobizkaia Hlth Res Inst, Bizkaia, Spain
[3] Univ Basque Country, UPV EHU, Bizkaia, Spain
[4] Hosp Univ Cruces, Hosp Univ Puerta Hierro Majadahonda, UNIR Hlth Sci Sch, Madrid, Spain
[5] Hosp Univ Cruces, Hosp Reg Univ Malaga, Malaga, Spain
[6] Univ Malaga, Malaga, Spain
[7] Bordeaux Univ Hosp, Bordeaux, France
关键词
D O I
10.1002/acr.25334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The objective of this study was to analyze the effect of methylprednisolone pulses (MP), given during the first year after the diagnosis of systemic lupus erythematosus (SLE), in achieving prolonged remission according to the degree of lupus activity at presentation. Methods. We conducted an observational study of routine clinical care data from the Lupus-Cruces-Bordeaux cohort. The end point was prolonged remission (ie, during five consecutive yearly visits). The effect of MP on remission during the first year was analyzed in the whole cohort and according to the baseline Systemic Lupus Erythematosus Disease Activity Index 2000 score: <6, 6 to 12, and >12, reflecting mild, moderate, and severe activity, respectively. For adjustment, logistic regression with propensity score (PS) and other therapeutic covariates was performed. Results. Two hundred thirty-three patients were included. Prolonged remission was achieved by 132 patients (57%). MP were associated with prolonged remission (PS-adjusted odds ratio [OR] 2.50, 95% confidence interval [CI] 1.04-623, P = 0.042). A strong clinical effect was seen among patients with moderate (adjusted OR 5.28, 95% CI 1.27-21.97, P = 0.022) and moderate-severe SLE activity (adjusted OR 4.07, 95% CI 1.11-14.82, P = 0.033). The administration of MP resulted in reduced average dosages of prednisone during the first year among patient with moderate (mean 6.6 vs 10.2 mg/day, P = 0.017) and severe activity (mean 14 vs 28 mg/day, P = 0.015). The odds of prolonged remission were increased by longer-term use of hydroxychloroquine (HCQ) and decreased by higher initial doses of prednisone. Conclusion. This study supports the use of MP to induce prolonged remission in patients with SLE, particularly in those with moderate and severe activity. The extended use of HCQ also contributes to achieve prolonged remission. image
引用
收藏
页码:1132 / 1138
页数:7
相关论文
共 50 条
  • [1] Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort
    Mok, C. C.
    Tse, S. M.
    Chan, K. L.
    Ho, L. Y.
    LUPUS, 2018, 27 (05) : 722 - 727
  • [2] Prolonged remission in systemic lupus erythematosus
    Feletar, M
    Ibanez, D
    Gladman, DD
    Urowitz, MB
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (08) : 1880 - 1880
  • [3] Prolonged remission in systemic lupus erythematosus
    Urowitz, MB
    Feletar, M
    Bruce, IN
    Ibañez, D
    Gladman, DD
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (08) : 1467 - 1472
  • [4] Intravenous pulses of methylprednisolone for systemic lupus erythematosus
    Badsha, H
    Edwards, CJ
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2003, 32 (06) : 370 - 377
  • [5] Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts
    Ruiz-Irastorza, Guillermo
    Ruiz-Estevez, Beatriz
    Lazaro, Estibaliz
    Ruiz-Arruza, Ioana
    Duffau, Pierre
    Martin-Cascon, Miguel
    Richez, Christophe
    Ugarte, Amaia
    Blanco, Patrick
    AUTOIMMUNITY REVIEWS, 2019, 18 (09)
  • [6] Cognitive function in a systemic lupus erythematosus inception cohort
    Petri, Michelle
    Naqibuddin, Mohammad
    Carson, Kathryn A.
    Sampedro, Margaret
    Wallace, Daniel J.
    Weisman, Michael H.
    Holliday, Stephen L.
    Padilla, Patricia A.
    Brey, Robin L.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (09) : 1776 - 1781
  • [7] Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus
    Steiman, Amanda J.
    Urowitz, Murray B.
    Ibanez, Dominique
    Papneja, Anjali
    Gladman, Dafna D.
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (09) : 1808 - 1816
  • [8] Prolonged remission (PR) in Systemic Lupus Erythematosus.
    Feleter, M
    Ibanez, D
    Urowitz, MB
    Gladman, DD
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S584 - S584
  • [9] Frequency and Characteristics of Prolonged Remission in Systemic Lupus Erythematosus
    Steiman, Amanda J.
    Urowitz, Murray B.
    Ibanez, Dominique
    Papneja, Anjali
    Gladman, Dafna D.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S543 - S544
  • [10] Belimumab in early systemic lupus erythematosus: A propensity score matching analysis
    Lu, Chaofan
    He, Nan
    Dou, Lei
    Yu, Hongxia
    Li, Mengtao
    Leng, Xiaomei
    Zeng, Xiaofeng
    IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (08)